Latest Insider Transactions at Hims & Hers Health, Inc. (HIMS)
This section provides a real-time view of insider transactions for Hims & Hers Health, Inc. (HIMS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Hims & Hers Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Hims & Hers Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 04
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,574
-8.82%
|
$657,462
$13.46 P/Share
|
Mar 04
2024
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,527
+17.04%
|
$202,635
$5.01 P/Share
|
Mar 04
2024
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
17,930
-86.71%
|
$251,020
$14.5 P/Share
|
Mar 04
2024
|
Irene Becklund PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,930
+46.44%
|
$161,370
$9.41 P/Share
|
Mar 01
2024
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
2,747
-50.0%
|
$35,711
$13.16 P/Share
|
Mar 01
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
144,448
-8.28%
|
$1,877,824
$13.07 P/Share
|
Mar 01
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
240,549
-100.0%
|
$3,127,137
$13.07 P/Share
|
Mar 01
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
188,896
+43.99%
|
$377,792
$2.43 P/Share
|
Feb 29
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
577,007
-91.78%
|
$6,924,084
$12.96 P/Share
|
Feb 29
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
577,007
+47.86%
|
$1,154,014
$2.43 P/Share
|
Feb 28
2024
|
David B Wells Director |
SELL
Open market or private sale
|
Direct |
260,000
-64.01%
|
$3,380,000
$13.16 P/Share
|
Feb 28
2024
|
Michael Chi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
47,687
-24.61%
|
$619,931
$13.19 P/Share
|
Feb 28
2024
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,000
-11.44%
|
$260,000
$13.19 P/Share
|
Feb 27
2024
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
2,747
-33.33%
|
$32,964
$12.08 P/Share
|
Feb 15
2024
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,972
-3.73%
|
$59,720
$10.04 P/Share
|
Feb 15
2024
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,972
+3.59%
|
$11,944
$2.43 P/Share
|
Feb 14
2024
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,109
-9.98%
|
$171,090
$10.0 P/Share
|
Feb 14
2024
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,109
+9.07%
|
$34,218
$2.43 P/Share
|
Feb 14
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
77,382
-59.97%
|
$696,438
$9.9 P/Share
|
Feb 14
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,382
+37.49%
|
$154,764
$2.43 P/Share
|
Feb 13
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
97,208
-65.3%
|
$874,872
$9.58 P/Share
|
Feb 13
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,208
+39.5%
|
$194,416
$2.43 P/Share
|
Feb 12
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
81,541
-61.22%
|
$733,869
$9.98 P/Share
|
Feb 12
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
81,541
+37.97%
|
$163,082
$2.43 P/Share
|
Feb 12
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
31,363
-16.68%
|
$313,630
$10.03 P/Share
|
Feb 12
2024
|
Oluyemi Okupe Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,385
+12.3%
|
$131,925
$5.01 P/Share
|
Feb 12
2024
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
22,839
-12.89%
|
$228,390
$10.03 P/Share
|
Feb 12
2024
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,839
+11.42%
|
$45,678
$2.43 P/Share
|
Feb 09
2024
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,509
-5.0%
|
$85,090
$10.03 P/Share
|
Feb 09
2024
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,080
-2.58%
|
$40,800
$10.03 P/Share
|
Feb 09
2024
|
Soleil Boughton Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,080
+2.51%
|
$8,160
$2.43 P/Share
|
Jan 29
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,100
-22.62%
|
$135,900
$9.01 P/Share
|
Jan 29
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,100
+18.45%
|
$30,200
$2.43 P/Share
|
Jan 26
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,940
-50.62%
|
$476,460
$9.11 P/Share
|
Jan 26
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
52,940
+33.61%
|
$105,880
$2.43 P/Share
|
Jan 25
2024
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
127,688
-71.2%
|
$1,149,192
$9.08 P/Share
|
Jan 25
2024
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
127,688
+41.59%
|
$255,376
$2.43 P/Share
|
Jan 02
2024
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,744
-8.18%
|
$109,952
$8.8 P/Share
|
Dec 29
2023
|
Melissa Baird Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
93,000
+8.7%
|
$186,000
$2.09 P/Share
|
Dec 29
2023
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,432
-29.32%
|
$192,888
$9.06 P/Share
|
Dec 29
2023
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,432
+22.68%
|
$42,864
$2.43 P/Share
|
Dec 28
2023
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,750
-33.27%
|
$231,750
$9.01 P/Share
|
Dec 28
2023
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,750
+24.96%
|
$51,500
$2.43 P/Share
|
Dec 27
2023
|
Andrew Dudum Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,700
-12.97%
|
$69,300
$9.02 P/Share
|
Dec 27
2023
|
Andrew Dudum Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,700
+11.48%
|
$15,400
$2.43 P/Share
|
Dec 20
2023
|
Soleil Boughton Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,450
-8.42%
|
$123,600
$8.71 P/Share
|
Dec 20
2023
|
Oluyemi Okupe Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,784
-1.94%
|
$54,272
$8.58 P/Share
|
Dec 19
2023
|
Lynne Chou O'Keefe Director |
SELL
Open market or private sale
|
Direct |
10,045
-100.0%
|
$80,360
$8.73 P/Share
|
Dec 19
2023
|
Irene Becklund PAO |
SELL
Open market or private sale
|
Direct |
10,597
-56.25%
|
$84,776
$8.73 P/Share
|
Dec 15
2023
|
Patrick Harrison Carroll Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,566
-5.19%
|
$76,528
$8.45 P/Share
|